Compare ZIM & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZIM | CELC |
|---|---|---|
| Founded | 1945 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.2B |
| IPO Year | 2020 | 2017 |
| Metric | ZIM | CELC |
|---|---|---|
| Price | $29.75 | $76.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $28.30 | ★ $160.75 |
| AVG Volume (30 Days) | ★ 1.4M | 703.8K |
| Earning Date | 11-19-2026 | 11-11-2026 |
| Dividend Yield | ★ 4.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.94 | N/A |
| Revenue Next Year | N/A | $979.15 |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.33 | $45.15 |
| 52 Week High | $30.96 | $151.02 |
| Indicator | ZIM | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 52.00 | 37.33 |
| Support Level | $27.23 | $77.84 |
| Resistance Level | $29.49 | $96.39 |
| Average True Range (ATR) | 0.86 | 3.64 |
| MACD | -0.21 | -0.37 |
| Stochastic Oscillator | 53.54 | 8.34 |
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.